We confirm that HER2 amplification is seen in all PAM50 subtypes, with more than half out- side of the HER2E subtype [15]. Only half of HER2E tumors are HER2A. A careful examination of the tran- scriptional HER2E subtype revealed that these tumors are enriched for ER-negative, yet ...
Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study Kluger H,DiVito K,Berger A,et al.Her2/neu is not a commonly expressed therapeutic target in melanoma – a large cohort tissue microarray study.Mel ......
Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the last few years, including the tyrosine kinase inhibitors (TKI) lapatinib, neratinib, tucatinib, and pyrotinib. These drug...
The HER2-negative breast cancer cell line, MCF-7, transfected to express CTF-611, showed exclusively red staining (ICD signal), confirming accurate detection of truncated HER2 generated by alternative translation initiation (Figure 1B). Compared with formalin-fixed cell-line pellets, breast cancer ...
The majority of PCI-6A cells, which had been generated from a primary tumour, were highly PRLR positive, whereas all PCI-6B cells generated from a metachronously developed corresponding lymph node metastasis were negative for PRLR, both on the cell surface and in the cytoplasm (Figure 1B). ...
No significant association with HER2/neu negativity was demonstrated. Contrasting results were obtained between CK5/6 and CK14 expression with respect to tumor grade and lymph node status. Conclusion: IHC can be used to identify patients with basal phenotype breast cancer with good sensitivity and ...
Moreover, bavituximab has been evaluated in several investigator-sponsored trials that include Her2-negative breast cancer, non-small cell lung cancer (NSCLC), hepato- cellular carcinoma, rectal carcinoma, advanced melanoma, and castrate-resistant prostate cancer. Finally, bavituximab is currently ...
The reason for this differential association with survival in the HER2 subtype is not known to date. Of note, a study by Spizzo et al (2002) suggests that concurrent EpCAM and HER2 expression may be associated with an additive negative impact on disease-related OS. In their study, however...
Biomarker analyses showed the tumor to be HER2 negative, p-MMR, MSS, TMB 0, with a CPS score of 0. She received several lines of systemic therapy (TS-1, XELOX, ramucirumab/paclitaxel, and PRL3zumab) prior to joining the PIANO trial. After 1 cycle of PIPAC OXA and 4 cycles of ...
As the original tumor was Her2 negative, if a genomic assay was then done on this patient, we would have identified the potential of CNS involvement. In conclusion, genomic assays should be routinely done on triple negative cancers. Keywords: triple negative, breast cancer, claudin high or low...